-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Press Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Press Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Press Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Press Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Press Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press Release
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
-
Press Release
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
-
Press Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)